AYTU BIOPHARMA, INC

Listed Company

AYTUCIK 0001385818NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30

Period

FY 2025

Revenue

$66.38M

Net Income

$-13.56M

Total Assets

$124.18M

Equity

$18.97M

Shares Out

10.73M

Op. Cash Flow

$-1.94M

AYTU$2.15−9.28% · past yearDBEQ Basic

Daily closing prices

Business

Aytu BioPharma is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases. The company commercializes prescription products including EXXUA (gepirone) for major depressive disorder, Adzenys and Cotempla (extended-release ADHD medications), and pediatric products including Karbinal and Poly-Vi-Flor/Tri-Vi-Flor. Products are sold primarily in the United States through third-party wholesalers, distributors, and pharmacies using a direct commercial organization and patient support platform.

Summary from 10-K filed 2025-09-23

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net revenue	66	65	107	97	66
Cost of goods sold	21	16	41	44	—
Gross profit	46	49	67	52	29
Selling and marketing	21	22	41	39	30
General and administrative	17	20	29	31	26
Research and development	1	3	4	13	6
Amortization of intangible assets	4	4	5	6	6
Restructuring costs	2	2	0	0	5
Impairment expense	8	0	6	75	13
Total operating expenses	54	51	84	162	88
Loss from operations	−8	−2	−17	−110	−59
Other (expense) income, net	−512,000	870,000	184,000	−757,000	−2
Interest expense	−4	−5	−5	—	—
Derivative warrant liabilities loss	−2	−4	5	2	0
Loss on extinguishment of debt	0	−594,000	—	169,000	−2
Loss from continuing operations before income tax expense	−14	−10	−17	−109	−58
Income tax expense	−400,000	−2	0	−110,000	259,000
Net loss from continuing operations	−14	−13	—	—	—
Net income (loss) from discontinued operations, net of tax	620,000	−3	—	—	—
Net loss	−14	−16	−17	−109	−58
Basic and diluted weighted-average common shares outstanding (in shares)	6	6	3	1	17
Basic and diluted - continuing operations (in dollars per share)	−2.26	−2.26	—	—	—
Basic and diluted - discontinued operations, net of tax (in dollars per share)	0.1	−0.6	—	—	—
Basic and diluted - net loss (in dollars per share)	−2.16	−2.86	−5.11	−74.01	−3.48

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash and cash equivalents	31	20	23	19	50
Accounts receivable, net	31	24	29	22	28
Inventories	11	12	12	11	16
Prepaid expenses and other current assets	6	5	—	—	—
Current assets of discontinued operations	0	1	—	—	—
Total current assets	79	62	73	60	105
Property and equipment, net	532,000	693,000	2	—	—
Operating lease right-of-use assets	1	829,000	2	3	4
Intangible assets, net	42	52	59	71	85
Other non-current assets	1	2	3	766,000	465,000
Non-current assets of discontinued operations	0	44,000	—	—	—
Total non-current assets	45	56	65	78	160
Total assets	124	118	136	138	266
Accounts payable	11	10	13	—	19
Accrued liabilities	38	38	47	44	57
Revolving credit facility	9	2	—	4	8
Current portion of debt	2	2	85,000	96,000	17
Other current liabilities	3	9	7	5	8
Current liabilities of discontinued operations	0	557,000	—	—	—
Total current liabilities	63	62	69	64	109
Debt, net of current portion	11	11	15	14	180,000
Derivative warrant liabilities	26	13	6	2	—
Other non-current liabilities	5	5	7	13	18
Total non-current liabilities	42	28	28	—	—
Commitments and contingencies (note 18)	—	—	—	—	—
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding	0	0	0	—	0
Common stock, par value $.0001; 200,000,000 shares authorized; 8,976,913 and 5,972,638 shares issued and outstanding, respectively	1,000	1,000	1,000	4,000	3,000
Additional paid-in capital	353	348	343	—	316
Accumulated deficit	−334	−320	−304	−287	−178
Total stockholders equity	19	28	39	44	138
Total liabilities and stockholders equity	124	118	136	138	266

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Depreciation, amortization and accretion	5	7	—	—	—
Stock-based compensation expense	576,000	2	6	5	4
Amortization of debt discount and issuance costs	108,000	597,000	559,000	−126,000	−44,000
Inventory write-down	300,000	1	2	2	7
Non-cash loss on extinguishment of debt	0	400,000	0	—	—
Other non-cash adjustments	752,000	471,000	7,000	—	—
Non-cash adjustments from discontinued operations	254,000	3	—	—	—
Accounts receivable, net	−8	5	−7	7	2
Inventories	382,000	−5	−4	1	3
Prepaid expenses and other current assets	−451,000	329,000	846,000	2	157,000
Accounts payable	287,000	−2	2	−8	−3
Accrued liabilities	886,000	−9	4	−13	771,000
Other operating assets and liabilities, net	528,000	4	−2	50,000	−332,000
Changes in operating assets and liabilities from discontinued operations	264,000	2	—	—	—
Net cash used in operating activities	−2	−1	−5	−29	−26
Cash received from sales of fixed assets	668,000	0	—	—	—
Cash payments for fixed asset purchases	−228,000	−329,000	—	—	—
Cash payments for acquired intangible assets	−3	0	—	—	—
Net cash used in investing activities	−3	−329,000	−117,000	−3	−3
Net proceeds from issuance of common stock and warrants	15	3	16	—	—
Payments made to fixed payment arrangement	−6	−3	−4	—	—
Net proceeds from revolving credit facility	7	832,000	−2	−4	—
Payments made to borrowings	−2	−16	−96,000	—	—
Proceeds from borrowings	2	13	—	—	—
Payments for debt issuance costs	−49,000	−273,000	−92,000	−526,000	0
Net cash provided by (used in) financing activities	15	−1	9	2	30
Net change in cash and cash equivalents	11	−3	4	−31	2
Cash payments for interest	3	4	4	3	1
Cash payments for income taxes	1	2	0	—	—
Other non-cash investing and financing activities	483,000	787,000	147,000	54,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AYTU BIOPHARMA, INC's CIK number?

AYTU BIOPHARMA, INC's SEC CIK number is 0001385818 (1385818). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AYTU BIOPHARMA, INC's SEC filings?

All of AYTU BIOPHARMA, INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AYTU BIOPHARMA, INC last report earnings?

AYTU BIOPHARMA, INC (AYTU) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-016717). This is AYTU BIOPHARMA, INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is AYTU BIOPHARMA, INC's most recent earnings 8-K?

AYTU BIOPHARMA, INC's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001437749-26-016717. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AYTU BIOPHARMA, INC's latest earnings 8-K →
Look up any company's CIK number →